JP2025503545A5 - - Google Patents
Info
- Publication number
- JP2025503545A5 JP2025503545A5 JP2024539560A JP2024539560A JP2025503545A5 JP 2025503545 A5 JP2025503545 A5 JP 2025503545A5 JP 2024539560 A JP2024539560 A JP 2024539560A JP 2024539560 A JP2024539560 A JP 2024539560A JP 2025503545 A5 JP2025503545 A5 JP 2025503545A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- level
- composition according
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163295213P | 2021-12-30 | 2021-12-30 | |
| US63/295,213 | 2021-12-30 | ||
| US202263349305P | 2022-06-06 | 2022-06-06 | |
| US63/349,305 | 2022-06-06 | ||
| PCT/US2022/082523 WO2023130001A1 (en) | 2021-12-30 | 2022-12-29 | Compositions and methods for treating huntington's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503545A JP2025503545A (ja) | 2025-02-04 |
| JP2025503545A5 true JP2025503545A5 (cg-RX-API-DMAC7.html) | 2025-12-26 |
Family
ID=87000332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024539560A Pending JP2025503545A (ja) | 2021-12-30 | 2022-12-29 | ハンチントン病を治療するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250074973A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4457244A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025503545A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240126863A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022425559A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313901A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024008273A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023130001A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3019240T3 (da) * | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| EP3380518B1 (en) * | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
-
2022
- 2022-12-29 US US18/725,580 patent/US20250074973A1/en active Pending
- 2022-12-29 JP JP2024539560A patent/JP2025503545A/ja active Pending
- 2022-12-29 AU AU2022425559A patent/AU2022425559A1/en active Pending
- 2022-12-29 EP EP22917557.5A patent/EP4457244A4/en active Pending
- 2022-12-29 IL IL313901A patent/IL313901A/en unknown
- 2022-12-29 KR KR1020247023399A patent/KR20240126863A/ko active Pending
- 2022-12-29 MX MX2024008273A patent/MX2024008273A/es unknown
- 2022-12-29 WO PCT/US2022/082523 patent/WO2023130001A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7293122B2 (ja) | 補体が媒介する疾患および障害を処置するための方法 | |
| US10100106B2 (en) | Single domain serum albumin binding protein | |
| CN104619724B (zh) | 识别α-突触核蛋白的人源化抗体 | |
| JP2022002524A5 (cg-RX-API-DMAC7.html) | ||
| CN110582511A (zh) | 抗N3pGlu淀粉状蛋白β肽抗体及其用途 | |
| TWI866304B (zh) | 抗EphA4抗體 | |
| AU2021267402A1 (en) | Bispecific antibodies against CD3 and CD20 | |
| JP2021526534A5 (cg-RX-API-DMAC7.html) | ||
| KR20250029157A (ko) | 보체-매개된 질환의 치료 방법 | |
| JP2024539141A5 (cg-RX-API-DMAC7.html) | ||
| JP2025503545A5 (cg-RX-API-DMAC7.html) | ||
| TW202321303A (zh) | 抗pla2r自體抗體媒介膜性腎病變之治療 | |
| JP2024515643A (ja) | 抗ヒトｍａｓｐ－２抗体、並びにその製造法及び使用 | |
| JP2023524819A5 (cg-RX-API-DMAC7.html) | ||
| JP2023504209A5 (cg-RX-API-DMAC7.html) | ||
| CN114605532B (zh) | 抗β-淀粉样蛋白抗体及其用途 | |
| US20250145696A1 (en) | Methods for treating complement-mediated diseases and disorders | |
| JP7692411B2 (ja) | 心血管疾患の治療用の内皮リパーゼ抗体 | |
| CN119677537A (zh) | 用于治疗狼疮性肾炎的组合物和方法 | |
| JP2023177377A (ja) | 多発性硬化症治療薬 | |
| JP2021518393A5 (cg-RX-API-DMAC7.html) | ||
| HK40022920A (en) | Methods for treating complement-mediated diseases and disorders |